# Amphastar Pharmaceuticals, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Amphastar Pharmaceuticals, Inc.).

## Overview

Amphastar Pharmaceuticals, Inc. develops, manufactures, and commercializes injectable and inhalation pharmaceutical products, with a portfolio that includes both branded and generic medicines. The company also performs contract manufacturing services and has built capabilities across finished dosage forms, APIs, and certain starting materials. Its business is centered on complex sterile and specialty products such as glucagon, epinephrine, phytonadione, and BAQSIMI®, alongside development-stage candidates. Amphastar operates as a single reportable segment, pharmaceutical products, and relies on a mix of U.S. and China manufacturing assets to support supply and future pipeline expansion.

## Products & services

• Injectable pharmaceutical products
• Inhalation products
• BAQSIMI® product rights and distribution
• Contract manufacturing services
• Active pharmaceutical ingredients (APIs)
• Starting materials and components
• Development-stage product candidates

- **Branded pharmaceutical products** (55%) — Commercial branded medicines such as BAQSIMI®, glucagon, epinephrine, Primatene MIST®, and phytonadione.
- **Generic injectable products** (25%) — Sterile injectable medicines sold into hospital and retail channels, including products like enoxaparin and nitroprusside.
- **Inhalation products** (8%) — Respiratory products sold through pharmacy and healthcare distribution channels.
- **Contract manufacturing services** (7%) — Third-party manufacturing services recognized when products are shipped to customers.
- **APIs and starting materials** (5%) — Internal and external supply of APIs, intermediates, and starting materials used in finished products and pipeline manufacturing.

- Injectable pharmaceutical products
- Inhalation products
- BAQSIMI® product rights and distribution
- Contract manufacturing services
- Active pharmaceutical ingredients (APIs)
- Starting materials and components
- Development-stage product candidates

## Customers

Amphastar sells primarily to wholesalers and distributors that then supply pharmacies, hospitals, and other end customers. A meaningful part of revenue is driven by prescription drug channels, where prompt-pay discounts, distributor fees, and patient co-pay assistance affect realized net sales. The company also serves third-party customers through contract manufacturing arrangements, where revenue is recognized upon shipment. Because its products include both branded and generic medicines, demand comes from a mix of healthcare providers, pharmacy channels, and procurement organizations seeking reliable supply and competitive pricing.

- **Wholesalers and pharmaceutical distributors** (primary) — Buy finished products in bulk for redistribution and are central to Amphastar's U.S. commercial model because they manage inventory, chargebacks, and downstream fulfillment.
- **Hospitals and healthcare systems** (primary) — Purchase injectable medicines used in acute care and procedural settings, where product availability and regulatory compliance matter.
- **Retail pharmacy channel** (secondary) — Buys branded and OTC-adjacent products such as Primatene MIST® and BAQSIMI® for patient dispensing.
- **Third-party pharmaceutical manufacturers** (secondary) — Use Amphastar's manufacturing capabilities for contract development and manufacturing services.
- **Patients and payers** (secondary) — Influence demand for prescription products through coverage, co-pay support, and formulary access even though they are not direct purchasers.

- Wholesalers and distributors buying finished drugs for downstream pharmacy supply
- Hospitals and healthcare systems purchasing injectable medicines through distribution channels
- Retail pharmacies dispensing products such as Primatene MIST® and BAQSIMI®
- Patients indirectly supported through co-pay assistance on prescription products
- Third-party pharmaceutical companies using Amphastar for contract manufacturing
- Healthcare buyers seeking supply continuity for sterile injectable products

## Geography

Amphastar is headquartered in the United States and generates most of its business through U.S.-based commercial and manufacturing operations. The company also operates a manufacturing facility in China, where it produces certain starting materials and APIs and plans further expansion. Management highlighted that all finished products and four APIs are manufactured in the United States, but the company still imports APIs, starting materials, and components from multiple countries, creating supply-chain exposure. Geography matters because the business depends on both domestic production capacity and cross-border sourcing, while tariffs, trade policy, and political conditions can affect cost and continuity. Foreign subsidiaries held cash outside the U.S., which limits immediate access to that liquidity for parent-company needs.

- United States is the core market for sales, regulation, and manufacturing
- China is a key manufacturing base for selected starting materials and APIs
- Some future API production is planned to come from the China facility
- Imported APIs and components create exposure to trade and tariff changes
- Foreign subsidiary cash is not freely available to fund U.S. operations
- U.S. FDA and DEA oversight shapes manufacturing and distribution requirements

## Strategy

Amphastar is focused on expanding its injectable and inhalation platform while integrating BAQSIMI® globally into its own revenue base. Management is investing in manufacturing upgrades and capacity expansion in both the United States and China to support current products and pipeline candidates. The company also continues to pursue product development, regulatory approvals, and strategic acquisitions to broaden its technology and manufacturing capabilities. This strategy is intended to reduce dependence on a narrow product set, improve supply resilience, and create longer-term growth from new launches and internal manufacturing control.

- **Expand manufacturing facilities and internal production capabilities** (medium-term) — Capacity, supply reliability, and cost control are central to a sterile injectable business with regulatory oversight and import exposure.
- **Grow BAQSIMI® and other commercial products** (short-term) — BAQSIMI® adds branded revenue and can improve mix, but requires successful commercialization and milestone management.
- **Advance pipeline products and regulatory approvals** (medium-term) — New launches are needed to offset product-level volatility and support longer-term growth.
- **Pursue strategic acquisitions** (medium-term) — Acquisitions can add technologies, manufacturing know-how, and commercial assets faster than organic development alone.

- Expand manufacturing capacity in the United States and China
- Integrate BAQSIMI® distribution globally into product revenues
- Advance development-stage product candidates through trials and approvals
- Use acquisitions to add manufacturing, marketing, and R&D capabilities
- Strengthen internal API and raw-material manufacturing capability
- Support future launches with a broader sterile and inhalation platform

## Risks

Amphastar faces meaningful concentration and execution risk around a relatively small set of commercial products, where sales of glucagon, epinephrine, and BAQSIMI® can fluctuate with competition and supply availability. The company also has material manufacturing and geopolitical exposure in China, where disruption, political unrest, tariffs, or regulatory changes could affect APIs and starting materials. Because the business depends on regulated sterile manufacturing, FDA and DEA compliance failures, plant interruptions, or quality issues could materially disrupt supply and sales. In addition, the company is exposed to pricing pressure from wholesalers, distributor fees, prompt-pay discounts, and patient assistance programs, while cyber and data-security incidents could impair operations, clinical data, or third-party relationships.

- **Manufacturing disruption in China** [high] — A portion of manufacturing takes place in China, including starting materials and APIs for several products, so plant disruption or political/trade changes could interrupt supply and raise costs.
- **Product sales volatility and competition** [high] — Management noted that glucagon, epinephrine, and other products can fluctuate based on competitive dynamics and competitor supply, which can quickly affect revenue mix.
- **Regulatory compliance and inspection risk** [high] — FDA and DEA oversight of formulation, manufacture, distribution, packaging, and labeling means any compliance issue can disrupt production or trigger remediation costs.
- **Tariff and trade policy exposure** [medium] — The company imports APIs, starting materials, and components from various countries, so tariffs or trade restrictions can increase input costs and complicate sourcing.
- **Cybersecurity and data loss** [medium] — A security incident could disrupt operations, compromise clinical or commercial data, and create legal and reputational harm.

- Product concentration risk from glucagon, epinephrine, and BAQSIMI®
- China manufacturing disruption, tariffs, and geopolitical instability
- FDA/DEA compliance risk for sterile and controlled-substance products
- Pricing pressure and competitive supply dynamics in injectable markets
- Supply-chain dependence on imported APIs, starting materials, and components
- Cybersecurity and data integrity risk across internal and third-party systems

## Accounting

Amphastar's revenue recognition is judgment-heavy because product sales are recorded net of prompt-pay discounts, distributor fees, and patient co-pay assistance, all of which require estimates at the time of sale. The company also recognizes contract manufacturing revenue when third-party products are shipped, so timing depends on shipment and contract structure rather than long-term percentage-of-completion accounting. BAQSIMI® created additional complexity because prior-period revenues included a net royalty-like TSA arrangement, while 2025 revenues are recognized in product revenues after Amphastar assumed global distribution responsibilities. Investors should also watch amortization and impairment risk in the company's large intangible asset base, especially the BAQSIMI® product rights, because future sales performance affects recoverability and reported earnings.

- **Revenue deductions and net sales estimates** — Affects net revenue, receivables, and accrued liabilities
- **BAQSIMI® revenue recognition and TSA transition** — Affects revenue comparability and gross margin
- **Intangible asset amortization and impairment** — Affects operating income and balance sheet carrying value
- **Inventory and channel-related estimates** — Affects revenue timing and accrued liabilities

- Net revenue deductions for prompt-pay discounts, chargebacks, and co-pay assistance
- Distributor fees reduce recognized product revenue and create accrued liabilities
- Contract manufacturing revenue is recognized on shipment, affecting quarter timing
- BAQSIMI® revenue presentation changed after global distribution was assumed in 2025
- Large intangible asset balances create amortization and impairment sensitivity
- Backlog is not meaningful, so quarterly revenue can be lumpy and order-driven

---

*Last updated: 2026-08-11T04:46:20.839891+00:00*